JNJ
Johnson & Johnson
$239.08
▲ 3.4%Updated Today 5:06 AM ET
▲ Up 51.5% over the last 12 months
Market Cap
$575.52B
P/E
27.37x
Forward P/E (est.)
28.48x
ROE
26.3%
Revenue Growth
7.9%
EPS Growth
-3.9%
Profit Margin
21.8%
FCF Yield
3.2%
Debt / Equity
0.59x
ROIC
14.0%
Interest Coverage
78.22x
Current Ratio
1.03x
Dividend Yield
2.3%
Implied Growth (rev. DCF)
5.4%
Rating Score
56/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what JNJ's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. JNJ trades near $239.08, above its 50-day average ($230.18) and 200-day average ($216.30). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 69 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. JNJ's is $5.31 (~2.2% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month JNJ found buyers near $220.84 (support) and sellers near $241.60 (resistance); its 52-week range is $149.74–$251.71. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.4× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Johnson & Johnson (JNJ) is a mega-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $575.52B.
In its latest reported year it generated about $94.19B in revenue and $26.80B in net profit.
Our model rates JNJ Neutral (56/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
3.3%
Revenue moved from $82.58B in 2021 to $94.19B in 2025, a 3.3% compound annual growth rate. The most recent year grew a steady 7.9% year over year. Slower, mature growth is common for established businesses.
Gross Margin
67.9%
Operating Margin
25.9%
Net Margin
28.5%
ROE
26.3%
Johnson & Johnson keeps about 21.8% of each sales dollar as net profit, with a 67.9% gross margin and 25.9% operating margin. Return on equity is 26.3% and return on invested capital about 14.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
$41.44B
Net Debt
$19.75B
Net Debt / EBITDA
—
Debt / Equity
0.59x
Leverage: debt-to-equity is 0.6x, and operating profit covers interest about 78.2x, with a current ratio of 1.0x. That is a moderate, manageable debt load for most businesses. It carries roughly $41.44B of total debt against $21.69B of cash.
Operating CF
$24.53B
Free Cash Flow
$19.70B
FCF Margin
20.9%
In the latest year Johnson & Johnson produced about $24.53B of operating cash flow and $19.70B of free cash flow after capital spending. That is a free-cash-flow yield of about 3.2% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
27.37x
P/S
6.01x
P/B
6.23x
EV / EBITDA
20.14x
JNJ trades at 27.4x trailing earnings (about 28.5x on estimated forward earnings), 6.0x sales, and 6.2x book value. Reverse-engineering today's price implies the market expects roughly 5.4% long-term free-cash-flow growth. That is a premium multiple that needs growth to justify it.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How JNJ stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), JNJ ranks #24 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (27.4x P/E vs. 25.5x median) with a higher return on equity (26.3% vs. 14.9%) and similar revenue growth (7.9% vs. 7.9%).
P/E vs sector
27.4x
median 25.5x
ROE vs sector
26.3%
median 14.9%
Growth vs sector
7.9%
median 7.9%
Sector rank
#24
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$257.57 – $434.65
vs. $239.08 today · expected CAGR 2% – 13%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $101.73B | $109.87B | $118.66B | $128.15B | $138.40B |
| Net income | $28.48B | $30.76B | $33.22B | $35.88B | $38.75B |
| EPS | $11.83 | $12.78 | $13.80 | $14.91 | $16.10 |
| Share price (low) | $189.32 | $204.47 | $220.83 | $238.49 | $257.57 |
| Share price (high) | $319.48 | $345.04 | $372.65 | $402.46 | $434.65 |
| CAGR (low–high) | -21% / 34% | -8% / 20% | -3% / 16% | -0% / 14% | 2% / 13% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for JNJ:
- High net margins (21.8%) point to pricing power or efficiency.
- Strong return on equity (26.3%) shows capital is put to work well.
- Pays a 2.3% dividend on top of any price gains.
The case against JNJ:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Johnson & Johnson is a mega-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 27.4x earnings, which our model scores Neutral (56/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
JNJ — frequently asked questions
Is JNJ a good stock to buy?
We don't give buy or sell advice. Our model rates Johnson & Johnson Neutral (56/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is JNJ's rating on The Stocks School?
Johnson & Johnson currently scores 56/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does JNJ's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Johnson & Johnson's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for JNJ calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this JNJ analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell JNJ. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.